Patheon to Showcase API Development Capabilities at InformEx - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Patheon to Showcase API Development Capabilities at InformEx

Patheon, a provider of contract development and commercial manufacturing services, will showcase its late-stage API development capabilities at InformEx in Miami, Fla., January 21-24, 2014. In addition, many Patheon executives as well as technical and scientific professionals will also attend InformEx and will be available to discuss Patheon's API development capabilities. Patheon will be exhibiting at Booth #1010 for the duration of the conference. InformEx offers participants a direct view of what is happening globally across the fine, specialty, and custom chemical marketplace. The event brings together an international mix of buyers and sellers for four days of sourcing, education, and networking.

Source: Patheon


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here